AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Ipatasertib|DRUG: Fulvestrant|DRUG: Aromatase Inhibitor|DRUG: Palbociclib
Sponsor: Massachusetts General Hospital
Collaborators: Genentech, Inc.